Business
Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373
Orally administered EB-373 resulted in dose-dependent increase in psilocin blood concentration in pharmacokinetic (PK) animal studies, correlating to levels
About this update from Enveric Biosciences, Inc.
[{"type":"text","content":"\nOrally administered EB-373 resulted in dose-dependent increase in psilocin blood concentration in pharmacokinetic (PK) animal studies, correlating to levels expected to be effective based on psilocybin data in humans\n\n\nOutcome of animal studies indicate potential to reduce GI upset and vomiting as well as rapid onset of action and systemic clearance, improving on PK characteristics of psilocybin\n\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nEnveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogen small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced positive results from PK animal studies demonstrating oral bioavailability, rapid onset of action and systemic clearance, and a more favorable side effect profile for the company’s lead product candidate, EB-373.\n\n\nPharmacokinetic (PK) measurements that were consistent in both dogs and rats confirmed that oral administration of EB-373, a psilocin-prodrug targeting anxiety disorders, resulted in dose-dependent increase in psilocin blood concentration, correlating to levels expected to be effective in humans. EB-373 demonstrated a very rapid conversion from prodrug to active metabolite psilocin, with concentrations of EB-373 that were approximately 100-fold lower in blood than psilocin and reached undetectable level after two hours. Additionally, psilocin blood concentration peaked at one hour after administration of EB-373 consistent with quicker onset of clinical effect.\n\n\nThe side effect profile was well tolerated overall, with notably no vomiting and no serious adverse events observed at any dose level.\n\n\n“In two oral animal PK studies, our novel drug candidate, EB-373, was shown to have dose-dependent and rapid release of psilocin corresponding with rapid onset of effect,” said Joseph Tucker, Ph.D., Director and CEO of Enveric. “Importantly, quickly converting the parent compound EB-373 to the active metabolite psilocin followed by its subsequent rapid elimination are critical PK properties designed to offer optimal control over the timing and length of the hallucinatory experience in humans alongside achieving the desired therapeutic effect.”\n\n\nDr. Tucker added, “EB-373 treated animals exhibited reduced overall side effects, i...